Skip to main content

Lamy Patrick's Form 4 filing

Akero Therapeutics, Inc. (AKRO) · filed May 9, 2025

Accession no.
0000950170-25-068392
Filed
May 9, 2025
Trade date
May 7, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $340.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lamy PatrickCIK 0001961273Officer (Senior VP, Commercial Strategy)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 7, 2025Common StockMOption exerciseAcquired+8,000$19.87+$158,96041,492Direct
May 7, 2025Common StockSSaleDisposed−4,701$42.31−$198,899.3136,791Direct
May 7, 2025Common StockSSaleDisposed−3,299$42.76−$141,065.2433,492Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 7, 2025Common StockMOption exerciseDisposed−8,000$0.00$070,182Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)